123 related articles for article (PubMed ID: 21333567)
1. Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.
Thamm DH; Rose B; Kow K; Humbert M; Mansfield CD; Moussy A; Hermine O; Dubreuil P
Vet J; 2012 Jan; 191(1):131-4. PubMed ID: 21333567
[TBL] [Abstract][Full Text] [Related]
2. Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.
Humbert M; Castéran N; Letard S; Hanssens K; Iovanna J; Finetti P; Bertucci F; Bader T; Mansfield CD; Moussy A; Hermine O; Dubreuil P
PLoS One; 2010 Mar; 5(3):e9430. PubMed ID: 20209107
[TBL] [Abstract][Full Text] [Related]
3. Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.
Hammam K; Saez-Ayala M; Rebuffet E; Gros L; Lopez S; Hajem B; Humbert M; Baudelet E; Audebert S; Betzi S; Lugari A; Combes S; Letard S; Casteran N; Mansfield C; Moussy A; De Sepulveda P; Morelli X; Dubreuil P
Nat Commun; 2017 Nov; 8(1):1420. PubMed ID: 29127277
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
Milovancev M; Helfand SC; Marley K; Goodall CP; Löhr CV; Bracha S
BMC Vet Res; 2016 Jun; 12():85. PubMed ID: 27259510
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the therapeutic potential of masitinib and expression of its specific targets c-Kit, PDGFR-α, PDGFR-β, and Lyn in canine prostate cancer cell lines.
Klose K; Packeiser EM; Granados-Soler JL; Hewicker-Trautwein M; Murua Escobar H; Nolte I
Vet Comp Oncol; 2022 Sep; 20(3):641-652. PubMed ID: 35384248
[TBL] [Abstract][Full Text] [Related]
6. Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.
Zandvliet M; Teske E; Chapuis T; Fink-Gremmels J; Schrickx JA
J Vet Pharmacol Ther; 2013 Dec; 36(6):583-7. PubMed ID: 23363222
[TBL] [Abstract][Full Text] [Related]
7. Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions.
Turek M; Gogal R; Saba C; Vandenplas ML; Hill J; Feldhausser B; Lawrence J
Res Vet Sci; 2014 Apr; 96(2):304-7. PubMed ID: 24602916
[TBL] [Abstract][Full Text] [Related]
8. Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells.
Fahey CE; Milner RJ; Kow K; Bacon NJ; Salute ME
Anticancer Drugs; 2013 Jun; 24(5):519-26. PubMed ID: 23466652
[TBL] [Abstract][Full Text] [Related]
9. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro.
Bourn J; Cekanova M
Drug Des Devel Ther; 2018; 12():1727-1742. PubMed ID: 29942116
[TBL] [Abstract][Full Text] [Related]
11. IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.
Bauer K; Hadzijusufovic E; Cerny-Reiterer S; Hoermann G; Reifinger M; Pirker A; Valent P; Willmann M
Vet Comp Oncol; 2017 Dec; 15(4):1240-1256. PubMed ID: 27507155
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
Avan A; Quint K; Nicolini F; Funel N; Frampton AE; Maftouh M; Pelliccioni S; Schuurhuis GJ; Peters GJ; Giovannetti E
Curr Pharm Des; 2013; 19(5):940-50. PubMed ID: 22973962
[TBL] [Abstract][Full Text] [Related]
13. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.
Mitry E; Hammel P; Deplanque G; Mornex F; Levy P; Seitz JF; Moussy A; Kinet JP; Hermine O; Rougier P; Raymond E
Cancer Chemother Pharmacol; 2010 Jul; 66(2):395-403. PubMed ID: 20364428
[TBL] [Abstract][Full Text] [Related]
14. Effects of gemcitabine and gemcitabine in combination with carboplatin on five canine transitional cell carcinoma cell lines.
de Brito Galvao JF; Kisseberth WC; Murahari S; Sutayatram S; Chew DJ; Inpanbutr N
Am J Vet Res; 2012 Aug; 73(8):1262-72. PubMed ID: 22849687
[TBL] [Abstract][Full Text] [Related]
15. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Nagaraj NS; Washington MK; Merchant NB
Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
Vermersch P; Brieva-Ruiz L; Fox RJ; Paul F; Ramio-Torrenta L; Schwab M; Moussy A; Mansfield C; Hermine O; Maciejowski M;
Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35190477
[TBL] [Abstract][Full Text] [Related]
17. Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.
McMahon MB; Bear MD; Kulp SK; Pennell ML; London CA
Am J Vet Res; 2010 Jul; 71(7):799-808. PubMed ID: 20594083
[TBL] [Abstract][Full Text] [Related]
18. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
Cadot P; Hensel P; Bensignor E; Hadjaje C; Marignac G; Beco L; Fontaine J; Jamet JF; Georgescu G; Campbell K; Cannon A; Osborn SC; Messinger L; Gogny-Goubert M; Dubreuil P; Moussy A; Hermine O
Vet Dermatol; 2011 Dec; 22(6):554-64. PubMed ID: 21668810
[TBL] [Abstract][Full Text] [Related]
19. Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.
Malone EK; Rassnick KM; Wakshlag JJ; Russell DS; Al-Sarraf R; Ruslander DM; Johnson CS; Trump DL
Vet Comp Oncol; 2010 Sep; 8(3):209-20. PubMed ID: 20691028
[TBL] [Abstract][Full Text] [Related]
20. c-kit inhibitor masitinib induces reactive oxygen species-dependent apoptosis in c-kit-negative HepG2 cells.
Semba Y; Yamamoto S; Takahashi S; Shinomiya T; Nagahara Y
Eur J Pharmacol; 2022 Sep; 931():175183. PubMed ID: 35940239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
